The recent move in ACADIA Pharmaceuticals (ACAD) stock follows a formal negative opinion from the EU’s CHMP on trofinetide for Rett syndrome, introducing fresh uncertainty around a potential European revenue stream.

The CHMP setback comes after a weak run in the share price, with a 7 day share price return of 9.77% and a 90 day share price return of 19.24%. However, the 1 year total shareholder return of 26.2% and 3 year total shareholder return of 8.79% remain positive. This suggests recent momentum has faded as investors reassess regulatory risk and the outlook for future cash flows, despite the latest earnings and 2026 revenue guidance.

If this news has you rethinking your biotech exposure, it could be a good time to look across neurology and rare disease peers using our 32 healthcare AI stocks.

With ACADIA trading at US$22.16 after a recent 90 day share price decline of 19.24%, but reporting US$1.07b in revenue and US$391 million in net income, should you see dislocation here or assume the market already prices in future growth?

Most Popular Narrative: 29% Undervalued

With ACADIA Pharmaceuticals closing at $22.16 against a narrative fair value of $31.21, the widely followed view sees meaningful upside grounded in long term CNS and rare disease assumptions.

ACADIA's pipeline momentum, with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027, positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.

Curious what earnings path needs to line up for that valuation to make sense? The narrative leans on steady revenue expansion, firm margins, and a richer future earnings multiple. The exact mix of those ingredients might surprise you.

Result: Fair Value of $31.21 (UNDERVALUED)

However, the picture can shift quickly if US price controls tighten around NUPLAZID’s Medicare heavy base or if key late stage trials in the 9 program pipeline fall short.

Next Steps

If this all sounds mixed to you, that is the point. Move quickly to check the underlying data and weigh it for yourself, starting with 4 key rewards.

Looking for more investment ideas?

If you stop here, you might miss companies that fit your goals even better, so take a few minutes to scan fresh ideas with the Simply Wall Street Screener.

• Spot potential mispricings by reviewing our 50 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them.
• Target resilience first and foremost by filtering for 63 resilient stocks with low risk scores that score well on financial and volatility checks.
• Hunt for earlier stage opportunities by scanning a 31 elite penny stocks with strong financials that pass stricter balance sheet and earnings filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.